Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Vasilios Liapis

Showing results (1-10 of 27) with videos related to

Pageof 3
Sort By:
Cancer Reports (Hoboken, N.J.)|October 12, 2021
The RNA-binding protein La/SSB associates with radiation-induced DNA double-strand breaks in lung cancer cell linesAlexander H Staudacher, Yanrui Li, Vasilios Liapis, et al.
Journal of Experimental & Clinical Cancer Research : CR|October 26, 2023
Antibody drug conjugates: hitting the mark in pancreatic cancer?Nicole L Wittwer, Michael P Brown, Vasilios Liapis, et al.
International Journal of Cancer|November 20, 2009
Zoledronic acid protects against osteosarcoma-induced bone destruction but lacks efficacy against pulmonary metastases in a syngeneic rat modelAgatha Labrinidis, Shelley Hay, Vasilios Liapis, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 30, 2009
Zoledronic acid inhibits both the osteolytic and osteoblastic components of osteosarcoma lesions in a mouse modelAgatha Labrinidis, Shelley Hay, Vasilios Liapis, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|September 18, 2020
Tumour-associated macrophages process drug and radio-conjugates of the dead tumour cell-targeting APOMAB® antibodyAlexander H Staudacher, Vasilios Liapis, William Tieu, et al.
Journal of Translational Medicine|June 12, 2025
Detection of immune-mediated tumour cell death in vivo using Zirconium-89-labeled APOMAB®Vasilios Liapis, Nicole L Wittwer, William Tieu, et al.
Journal for Immunotherapy of Cancer|March 6, 2023
An anti-mesothelin targeting antibody drug conjugate induces pyroptosis and ignites antitumor immunity in mouse models of cancerNicole L Wittwer, Alexander H Staudacher, Vasilios Liapis, et al.
Biomaterials|February 14, 2015
Systematic in vitro nanotoxicity study on anodic alumina nanotubes with engineered aspect ratio: understanding nanotoxicity by a nanomaterial modelYe Wang, Gagandeep Kaur, Aneta Zysk, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|May 14, 2022
Fc gamma receptor is not required for in vivo processing of radio- and drug-conjugates of the dead tumor cell-targeting monoclonal antibody, APOMAB®Alexander H Staudacher, Vasilios Liapis, Nicole L Wittwer, et al.
EJNMMI Radiopharmacy and Chemistry|November 18, 2020
Improved non-invasive positron emission tomographic imaging of chemotherapy-induced tumor cell death using Zirconium-89-labeled APOMAB®Vasilios Liapis, William Tieu, Stacey E Rudd, et al.
Pageof 3

Showing results (1-10 of 27) with videos related to

Sort By:
Pageof 3
Cancer Reports (Hoboken, N.J.)|October 12, 2021
The RNA-binding protein La/SSB associates with radiation-induced DNA double-strand breaks in lung cancer cell linesAlexander H Staudacher, Yanrui Li, Vasilios Liapis, et al.
Journal of Experimental & Clinical Cancer Research : CR|October 26, 2023
Antibody drug conjugates: hitting the mark in pancreatic cancer?Nicole L Wittwer, Michael P Brown, Vasilios Liapis, et al.
International Journal of Cancer|November 20, 2009
Zoledronic acid protects against osteosarcoma-induced bone destruction but lacks efficacy against pulmonary metastases in a syngeneic rat modelAgatha Labrinidis, Shelley Hay, Vasilios Liapis, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 30, 2009
Zoledronic acid inhibits both the osteolytic and osteoblastic components of osteosarcoma lesions in a mouse modelAgatha Labrinidis, Shelley Hay, Vasilios Liapis, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|September 18, 2020
Tumour-associated macrophages process drug and radio-conjugates of the dead tumour cell-targeting APOMAB® antibodyAlexander H Staudacher, Vasilios Liapis, William Tieu, et al.
Journal of Translational Medicine|June 12, 2025
Detection of immune-mediated tumour cell death in vivo using Zirconium-89-labeled APOMAB®Vasilios Liapis, Nicole L Wittwer, William Tieu, et al.
Journal for Immunotherapy of Cancer|March 6, 2023
An anti-mesothelin targeting antibody drug conjugate induces pyroptosis and ignites antitumor immunity in mouse models of cancerNicole L Wittwer, Alexander H Staudacher, Vasilios Liapis, et al.
Biomaterials|February 14, 2015
Systematic in vitro nanotoxicity study on anodic alumina nanotubes with engineered aspect ratio: understanding nanotoxicity by a nanomaterial modelYe Wang, Gagandeep Kaur, Aneta Zysk, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|May 14, 2022
Fc gamma receptor is not required for in vivo processing of radio- and drug-conjugates of the dead tumor cell-targeting monoclonal antibody, APOMAB®Alexander H Staudacher, Vasilios Liapis, Nicole L Wittwer, et al.
EJNMMI Radiopharmacy and Chemistry|November 18, 2020
Improved non-invasive positron emission tomographic imaging of chemotherapy-induced tumor cell death using Zirconium-89-labeled APOMAB®Vasilios Liapis, William Tieu, Stacey E Rudd, et al.
Pageof 3